RU2006127552A - Слитые белки il-7 - Google Patents
Слитые белки il-7 Download PDFInfo
- Publication number
- RU2006127552A RU2006127552A RU2006127552/13A RU2006127552A RU2006127552A RU 2006127552 A RU2006127552 A RU 2006127552A RU 2006127552/13 A RU2006127552/13 A RU 2006127552/13A RU 2006127552 A RU2006127552 A RU 2006127552A RU 2006127552 A RU2006127552 A RU 2006127552A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- amino acid
- constant domain
- modification
- glycosylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (28)
1. Слитый белок IL-7, включающий цепочку иммуноглобулина и молекулу IL-7, которая является модифицированной по сравнению с IL-7 дикого типа, связанные вместе непосредственно или посредством молекулы линкера, где модификация в IL-7 представляет собой
(i) аминокислотные остатки в положениях 70 и 91 являются гликозилированными, а аминокислотный остаток в положении 116 является негликозилированным;
и/или (ii) в пределах остатка IL-7 существуют дисульфидные связи между Cys2 и Cys92, Cys34 и Cys129 и Cys47 и Cys141.
2. Слитый белок IL-7 по п.1, в котором аминокислотные остатки в положениях 70 и 91 IL-7 являются гликозилированными, а аминокислотный остаток в положении 116 IL-7 является негликозилированным, и существуют дисульфидные связи в пределах остатка IL-7 между Cys2 и Cys92, Cys34 и Cys129 и Cys47 и Cys141.
3. Слитый белок IL-7 по п.1, в котором аминокислотный остаток в положении 116 представляет собой аспарагин.
4. Слитый белок IL-7 по п.1, в котором аминокислотный остаток в положении 116 является негликозилированным.
5. Слитый белок IL-7 по п.1, в котором аминокислотный остаток в положении 116 является измененным так, что он не служит сайтом гликозилирования.
6. Слитый белок IL-7 по п.1, в котором молекула IL-7 включает делецию.
7. Слитый белок IL-7 по п.6, в котором укороченный IL-7 включает делецию восемнадцати аминокислот от аминокислоты 96 до аминокислоты 114 SEQ ID NO: 1.
8. Слитый белок IL-7 по п.1, в котором молекула IL-7 представляет собой IL-7 человека.
9. Слитый белок IL-7 по п.1, в котором IL-7 представляет собой остаток зрелого IL-7.
10. Слитый белок IL-7 по п.1, в котором цепочка иммуноглобулина включает, по крайней мере, часть константного домена.
11. Слитый белок IL-7 по п.10, в котором константный домен является выбранным из группы, состоящей из СН1, СН2 и СН3.
12. Слитый белок IL-7 по п.10, в котором константный домен представляет собой константный домен IgG1.
13. Слитый белок IL-7 по п.12, в котором Asn297 константного домена IgG1 является модифицированным.
14. Слитый белок IL-7 по п.13, в котором модификация Asn297 представляет собой Asn297Gln.
15. Слитый белок IL-7 по п.13, который дополнительно включает модификацию в Тyr296.
16. Слитый белок IL-7 по п.15, в котором модификация Тyr296 представляет собой Тyr296Аlа.
17. Слитый белок IL-7 по п.10, в котором константный домен представляет собой константный домен IgG2.
18. Слитый белок IL-7 по п.17, в котором цепочка IgG2 включает шарнир IgG1.
19. Слитый белок IL-7 по п.17, в котором Asn297 константного домена IgG2 является модифицированным.
20. Слитый белок IL-7 по п.19, в котором модификация Asn297 представляет собой Asn297Gln.
21. Слитый белок IL-7 по п.19, дополнительно включающий модификацию в Phe296.
22. Слитый белок IL-7 по п.21, в котором модификация Phe296 представляет собой Phe296Ala.
23. Слитый белок IL-7 по п.1 или 2, в котором остаток IL-7 слитого белка обладает повышенной биологической активностью по сравнению с IL-7 дикого типа.
24. Изолированная молекула ДНК, кодирующая слитый белок IL-7 по любому из пп.1-23.
25. Культивируемая хозяйская клетка, включающая ДНК по п.24.
26. Способ получения слитого белка, включающий: трансформацию хозяйской клетки с помощью ДНК по п.24, культивирование хозяйской клетки, а также экспрессию и сбор слитого белка IL-7.
27. Фармацевтическая композиция, приемлемая для лечения иммунных расстройств или рака, включающая фармацевтически эффективное количество слитого белка IL-7 по любому из пп.1-23, необязательно вместе с фармацевтически приемлемым носителем, разбавителем или наполнителем.
28. Применение слитого белка IL-7 по любому из пп.1-23 для получения лекарственного средства для лечения иммунных дефицитов и рака.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53340603P | 2003-12-30 | 2003-12-30 | |
| US60/533,406 | 2003-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006127552A true RU2006127552A (ru) | 2008-02-10 |
| RU2369616C2 RU2369616C2 (ru) | 2009-10-10 |
Family
ID=34738862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006127552/13A RU2369616C2 (ru) | 2003-12-30 | 2004-12-21 | Слитые белки il-7 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7323549B2 (ru) |
| EP (1) | EP1699822B1 (ru) |
| JP (1) | JP2008502317A (ru) |
| KR (1) | KR101163424B1 (ru) |
| CN (1) | CN100467488C (ru) |
| AT (1) | ATE393169T1 (ru) |
| AU (1) | AU2004309050B2 (ru) |
| BR (1) | BRPI0418286A (ru) |
| CA (1) | CA2551915C (ru) |
| DE (1) | DE602004013372T2 (ru) |
| DK (1) | DK1699822T3 (ru) |
| ES (1) | ES2305886T3 (ru) |
| PL (1) | PL1699822T3 (ru) |
| PT (1) | PT1699822E (ru) |
| RU (1) | RU2369616C2 (ru) |
| WO (1) | WO2005063820A2 (ru) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| AU2001296962A1 (en) | 2000-09-29 | 2002-04-08 | Schering Corporation | Pegylated interleukin-10 |
| PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
| BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| EP1391513A1 (en) * | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
| BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1819728B1 (en) * | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7 variants with reduced immunogenicity |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| EP1966238B1 (en) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40 variants with improved stability |
| PT1966245E (pt) * | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| BRPI0719446A2 (pt) | 2006-09-28 | 2013-12-10 | Schering Corp | Uso de il-10 peguilada para tratar câncer |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| KR102467302B1 (ko) * | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| KR20120030383A (ko) * | 2009-04-22 | 2012-03-28 | 메르크 파텐트 게엠베하 | 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질 |
| JP6048845B2 (ja) | 2011-06-01 | 2016-12-21 | シャモン ユニヴァーシティー | ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質 |
| CA2843495A1 (en) * | 2011-08-03 | 2013-02-07 | Cytheris | Hcv immunotherapy |
| WO2013074489A1 (en) * | 2011-11-14 | 2013-05-23 | Emory University | Conjugates of gm-csf and il-7, compositions and methods related thereto |
| JP2015505843A (ja) * | 2011-12-15 | 2015-02-26 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| US8718729B1 (en) | 2012-10-31 | 2014-05-06 | Timothy Kershenstein | Electronic device protection system |
| JP6456356B2 (ja) * | 2013-03-15 | 2019-01-23 | ジェネンテック， インコーポレイテッド | ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法 |
| IL240561B (en) * | 2013-03-15 | 2020-10-29 | Genentech Inc | il–22 polypeptides and fc il–22 fusion proteins and methods of use |
| CA2908198A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
| MX2016005915A (es) | 2013-11-11 | 2016-12-16 | Armo Biosciences Inc | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3302547A1 (en) | 2015-05-28 | 2018-04-11 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| WO2016200219A1 (en) | 2015-06-11 | 2016-12-15 | Genexine, Inc. | Modified interleukin-7 protein and uses thereof |
| CN106397571A (zh) * | 2015-07-31 | 2017-02-15 | 李金松 | 一种新型羧基末端肽及长效白介素7 |
| WO2017035232A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| KR102386735B1 (ko) * | 2015-11-06 | 2022-04-14 | 주식회사 제넥신 | 변형된 인터루킨-7 융합 단백질의 제형 |
| CN108697764A (zh) | 2015-12-04 | 2018-10-23 | 格纳西尼有限公司 | 含有免疫球蛋白fc融合白细胞介素-7融合蛋白的用于预防或治疗流感病毒感染的药物组合物 |
| KR20170066265A (ko) * | 2015-12-04 | 2017-06-14 | 주식회사 제넥신 | 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물 |
| KR20180091918A (ko) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3802619A1 (en) * | 2018-06-08 | 2021-04-14 | F. Hoffmann-La Roche AG | Peptidic linker with reduced post-translational modification |
| BR122021012517A2 (pt) | 2018-08-06 | 2021-08-10 | Medikine, Inc. | Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante |
| US20220008515A1 (en) | 2018-11-16 | 2022-01-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| CN114555190A (zh) * | 2019-05-16 | 2022-05-27 | 安驰肿瘤公司 | 与白介素蛋白的类似物组合治疗癌症的治疗性组合物和方法 |
| US11512122B2 (en) | 2019-05-17 | 2022-11-29 | Xencor, Inc. | IL-7-FC-fusion proteins |
| WO2021046404A1 (en) * | 2019-09-04 | 2021-03-11 | Genexine, Inc. | Method for increasing lymphocyte count by using il-7 fusion protein in tumors |
| US11248030B2 (en) * | 2019-11-05 | 2022-02-15 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
| BR112022008744A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
| WO2021096275A1 (ko) * | 2019-11-15 | 2021-05-20 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| IL294663A (en) | 2020-01-13 | 2022-09-01 | Neoimmunetech Inc | A method for tumor treatment with a combination of il-7 protein and a bispecific antibody |
| US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| EP4100045A1 (en) | 2020-02-05 | 2022-12-14 | Washington University | Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells |
| US20210324027A1 (en) * | 2020-04-16 | 2021-10-21 | Genexine, Inc. | Modified interleukin-7 proteins and uses thereof |
| WO2022093718A1 (en) | 2020-10-26 | 2022-05-05 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
| WO2022094475A1 (en) | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| JP2023549112A (ja) | 2020-11-05 | 2023-11-22 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法 |
| WO2022115396A1 (en) * | 2020-11-25 | 2022-06-02 | Jecho Laboratories, Inc. | Il-7 fusion protein and related methods |
| JP2023554097A (ja) * | 2020-12-17 | 2023-12-26 | オーエスイー・イミュノセラピューティクス | 二機能性抗ｐｄ１／ｉｌ－７分子 |
| IL307419A (en) * | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
| WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
| WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
| CN117050178B (zh) * | 2023-10-13 | 2024-01-12 | 北京百普赛斯生物科技股份有限公司 | 特异性检测il-7的抗体及应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
| US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
| EP0305967B1 (de) | 1987-09-02 | 1993-05-05 | Ciba-Geigy Ag | Konjugate von Interferon alpha mit Immunglobulinen |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Ｈｉｖ感染細胞に殺作用する抗体異種結合体 |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
| US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| ATE123065T1 (de) | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | Proteine und deren herstellung. |
| GB8916400D0 (en) * | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
| US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1993005169A1 (en) | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
| US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
| US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| US5281010A (en) * | 1992-11-19 | 1994-01-25 | Allied-Signal Inc. | Pumpback adaptive braking system with slave isolation valve |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| ATE207366T1 (de) * | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| DE69523857T2 (de) | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | Immunokonjugate |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6410008B1 (en) * | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| ATE271606T1 (de) | 1995-03-10 | 2004-08-15 | Genentech Inc | Die aktivierung von rezeptoren durch gas6 |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| MXPA00010070A (es) | 1998-04-15 | 2004-03-10 | Lexigen Pharm Corp | Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis. |
| CA2328081A1 (en) | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| WO1999054484A1 (en) | 1998-04-20 | 1999-10-28 | The Regents Of The University Of California | Modified immunoglobulin molecules and methods for use thereof |
| AU751823B2 (en) | 1998-05-14 | 2002-08-29 | Merck Patent Gmbh | Fused protein |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| DK1107989T3 (da) | 1998-08-25 | 2010-05-25 | Merck Patent Gmbh | Ekspression og eksport af angiostatin og endostatin som immunfusiner |
| US6646113B1 (en) | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
| US6335176B1 (en) | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
| CN1341121A (zh) | 1999-01-07 | 2002-03-20 | 利思进药品公司 | 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运 |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| JP2003528573A (ja) | 1999-05-06 | 2003-09-30 | ウエイク・フオレスト・ユニバーシテイ | 免疫応答を導き出す抗原を同定するための組成物および方法 |
| MXPA01011845A (es) | 1999-05-19 | 2002-06-21 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc. |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP5179689B2 (ja) * | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| PT1257297E (pt) | 2000-02-24 | 2006-12-29 | Philogen Spa | Composições e método para tratamento da angiogénese em lesões patológicas |
| EP1285072A2 (en) | 2000-05-12 | 2003-02-26 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
| RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| BR0116803A (pt) | 2001-01-18 | 2004-02-17 | Merck Patent Gmbh | Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase |
| ES2309167T3 (es) | 2001-02-19 | 2008-12-16 | Merck Patent Gmbh | Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida. |
| US7189830B2 (en) | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| PL206701B1 (pl) * | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
| BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7395159B2 (en) * | 2002-07-26 | 2008-07-01 | Obi Aps | Method, system and devices for converting venous blood values to arterial blood values |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| MXPA05006384A (es) * | 2002-12-17 | 2005-08-29 | Merck Patent Gmbh | Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2. |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| US20050025573A1 (en) | 2003-07-31 | 2005-02-03 | Waldman John Jeffrey | Liquid control structure |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
| BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| PT1706428E (pt) * | 2004-01-22 | 2009-12-29 | Merck Patent Gmbh | Anticorpos anticancerígenos com fixação de complemento reduzida |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1819728B1 (en) * | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7 variants with reduced immunogenicity |
| CN100480953C (zh) * | 2005-01-10 | 2009-04-22 | 新科实业有限公司 | 短尾读写头万向架组件测试夹具 |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CN101346395A (zh) | 2005-12-30 | 2009-01-14 | 默克专利有限公司 | 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体 |
| PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| EP1966238B1 (en) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40 variants with improved stability |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
-
2004
- 2004-12-21 AU AU2004309050A patent/AU2004309050B2/en not_active Ceased
- 2004-12-21 BR BRPI0418286-3A patent/BRPI0418286A/pt not_active IP Right Cessation
- 2004-12-21 KR KR1020067013033A patent/KR101163424B1/ko not_active IP Right Cessation
- 2004-12-21 CA CA2551915A patent/CA2551915C/en not_active Expired - Fee Related
- 2004-12-21 PT PT04804151T patent/PT1699822E/pt unknown
- 2004-12-21 CN CNB2004800389071A patent/CN100467488C/zh not_active Expired - Fee Related
- 2004-12-21 WO PCT/EP2004/014555 patent/WO2005063820A2/en active IP Right Grant
- 2004-12-21 DK DK04804151T patent/DK1699822T3/da active
- 2004-12-21 ES ES04804151T patent/ES2305886T3/es active Active
- 2004-12-21 DE DE602004013372T patent/DE602004013372T2/de active Active
- 2004-12-21 AT AT04804151T patent/ATE393169T1/de active
- 2004-12-21 EP EP04804151A patent/EP1699822B1/en not_active Not-in-force
- 2004-12-21 PL PL04804151T patent/PL1699822T3/pl unknown
- 2004-12-21 JP JP2006546044A patent/JP2008502317A/ja active Pending
- 2004-12-21 RU RU2006127552/13A patent/RU2369616C2/ru not_active IP Right Cessation
- 2004-12-30 US US11/027,446 patent/US7323549B2/en active Active
-
2007
- 2007-12-04 US US11/950,073 patent/US7960514B2/en not_active Expired - Fee Related
-
2011
- 2011-05-18 US US13/110,359 patent/US8338575B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL1699822T3 (pl) | 2008-08-29 |
| DK1699822T3 (da) | 2008-08-04 |
| BRPI0418286A (pt) | 2007-05-02 |
| US20090010875A1 (en) | 2009-01-08 |
| WO2005063820A2 (en) | 2005-07-14 |
| AU2004309050B2 (en) | 2010-10-14 |
| CA2551915A1 (en) | 2005-07-14 |
| DE602004013372T2 (de) | 2009-07-02 |
| AU2004309050A1 (en) | 2005-07-14 |
| ATE393169T1 (de) | 2008-05-15 |
| CA2551915C (en) | 2015-06-23 |
| KR101163424B1 (ko) | 2012-07-13 |
| WO2005063820A3 (en) | 2006-03-09 |
| US7323549B2 (en) | 2008-01-29 |
| US7960514B2 (en) | 2011-06-14 |
| JP2008502317A (ja) | 2008-01-31 |
| US8338575B2 (en) | 2012-12-25 |
| EP1699822A2 (en) | 2006-09-13 |
| EP1699822B1 (en) | 2008-04-23 |
| PT1699822E (pt) | 2008-07-30 |
| CN100467488C (zh) | 2009-03-11 |
| ES2305886T3 (es) | 2008-11-01 |
| US20050164352A1 (en) | 2005-07-28 |
| KR20060112673A (ko) | 2006-11-01 |
| CN1898262A (zh) | 2007-01-17 |
| DE602004013372D1 (de) | 2008-06-05 |
| US20110243887A1 (en) | 2011-10-06 |
| RU2369616C2 (ru) | 2009-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006127552A (ru) | Слитые белки il-7 | |
| RU2006127554A (ru) | Fc-эритропоэтин слитый белок с улучшенной фармакокинетикой | |
| JP4188353B2 (ja) | 強化ワクチン | |
| TWI501776B (zh) | 抗ｉｌ－１２／ｉｌ－２３抗體 | |
| US11028398B2 (en) | Fusion proteins having mutated immunoglobulin hinge region | |
| RU2008116323A (ru) | Конъюгаты интерлейкина-1 и их применение | |
| RU2008134389A (ru) | Рекомбинантные слитые человеческие белки epo-fc с продленным временем полужизни и повышенной эритропоэтической активностью in vivo | |
| CN1294596A (zh) | 修饰蛋白的免疫原性 | |
| KR100393508B1 (ko) | 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질 | |
| TW201336865A (zh) | 免疫球蛋白Ｆｃ變體 | |
| KR20120093932A (ko) | Ｉｌ－１７ 패밀리 사이토카인 조성물들 및 용도들 | |
| WO2005024044A3 (en) | Method for the production of fusion proteins in transgenic mammal milk | |
| CN1374871A (zh) | 增强蛋白和肽抗原免疫原性的Fc融合蛋白 | |
| EA017303B1 (ru) | Модифицированные гуманизированные антитела против интерлейкина-18 и их применение | |
| EP3892632A1 (en) | Modified product of fc domain of antibody | |
| KR19990063653A (ko) | 케모킨 억제제 | |
| EA003942B1 (ru) | Усеченный по амино-концу моноцитарный хемотаксический белок (mcp-2) и способы его использования | |
| CN102875683B (zh) | 长效重组人生长激素的Fc融合蛋白 | |
| CN1088616A (zh) | 大潜在转化生长因子-β复合物及其有用结构物的生产方法 | |
| DE60227367D1 (de) | Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität | |
| EP0866871A1 (en) | Compositions and method for stimulating antibody release by b lymphocytes | |
| RU2214279C2 (ru) | Усовершенствованные вакцины | |
| CN109824780A (zh) | 一种用于研发药物的双功能融合蛋白平台 | |
| EP1621209A2 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides | |
| RU2385875C2 (ru) | Пептид, обладающий ростостимулирующей активностью гранулоцитарного колониестимулирующего фактора человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20121222 |